A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

Who May Qualify: - Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1) - Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study. Who Should NOT Join This Trial: - Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1). - Those who are expected to need insulin prescription during the study period. Always talk to your doctor about whether this trial is right for you.